Navigation Links
Celsion Receives SBIR Grant To Expand Its Technology Platform
Date:9/2/2010

COLUMBIA, Md., Sept. 2 /PRNewswire-FirstCall/ --Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".  This funding will support the Company's efforts to develop its proprietary heat-activated liposomal technology in combination with carboplatin, an approved and frequently used oncology drug for treatment of a wide range of cancers.  The grant is valued at approximately $200,000 and will support formulation development and preclinical efficacy studies in collaboration with Duke University.  

"NIH's support of Celsion's unique research focus is evident with this grant and represents a continuation of the Institute's interest in the value of our platform heat sensitive liposomal technology to treat certain difficult cancers; most notably reflected in our ThermoDox® clinical program.  This initial funding will provide important financial assistance as we further expand our technology platform to incorporate known anticancer agents.  Our initial market assessment indicates that thermosensitive Carboplatin has the potential to address multiple solid tumor indications that are not addressed by ThermoDox, but could be an optimal adjuvant to radiofrequency ablation, microwave or high intensity ultrasound. As we commence our preclinical studies, we will work closely with the medical and regulatory communities and identify an optimal approval path," said Michael Tardugno, President and CEO of Celsion.  "The work conducted under this grant may lead to the development of improved treatments for a wide range of cancers."

Celsion's lead product candidate, ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is currently being evaluated in the Phase III HEAT trial for the treatment of hepatocellular carcinoma (HCC) and in a Phase I/II trial for patients with recurrent chest wall breast cancer.  Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of a known chemotherapeutic agent to be deposited preferentially in a targeted tumor.

About CelsionCelsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System. Investor ContactMarcy NanusThe Trout Group646-378-2927 or mnanus@troutgroup.comFor more information on Celsion, visit our website: http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Celsion Announces CFO Departure
2. Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... Tuesday, August 8, 2017.  Members of its senior management team will ... open at 8:30 a.m. ET. The dial-in number ... 497-0462, International (678) 509-7598, and the passcode is 45397076. Please dial ... A replay of the call will ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)...  Eli Lilly and Company (NYSE: LLY ) ... resolve pending patent litigation in the U.S. District Court for ... the Cialis ® (tadalafil) unit dose patent. This patent ... part of the agreement, Cialis exclusivity is now expected to ... "The unit dose patent for Cialis is valid and infringed ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... On July 19th, ... set up, and the awarding ceremony was held successfully in Beijing. The State ... the army's health system, and national Chinese medicine experts also attended the event, ...
(Date:7/24/2017)... ... July 24, 2017 , ... “The Perfect Gift”: a customizable and interactive Bible study guide ... Huckett is a born-again Christian. She has always accepted Christ as her Savior, yet ... She was in the Spirit when she wrote this book to her children, so they ...
(Date:7/24/2017)... ... July 24, 2017 , ... “A Short Walk to the ... Mailbox” is the creation of published author, Ed Clark. Ed Clark is a ... Christian Reformed churches as a minister of music and worship leader for over fifty ...
(Date:7/24/2017)... ... 2017 , ... The Center for Addiction Recovery Training (CART), ... a second Multiple Pathways of Recovery Conference on October 23-26, 2017. This year, ... CCAR’s foundational principle – a belief in multiple pathways of recovery, aims to ...
(Date:7/23/2017)... IL (PRWEB) , ... July ... ... of Eating Disorders Professionals ™(iaedp), the leading provider of education and training ... training in preparation for competency for Traditional Certification: the iaedp™ Core Curriculum. ...
Breaking Medicine News(10 mins):